Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ISIS 183750 + carboplatin + paclitaxel
- Development stage
- Discontinued
- Lead developer
- Ionis Pharmaceuticals
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Molecules, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intravenous
01
Overview
ISIS 183750 + carboplatin + paclitaxel is a combination regimen consisting of ISIS 183750 (a second-generation antisense oligonucleotide targeting eukaryotic initiation factor 4E, or eIF4E), carboplatin (a platinum-based DNA cross-linker antineoplastic agent), and paclitaxel (a microtubule-stabilizing antineoplastic agent). ISIS 183750 (also known as ISIS EIF4E Rx) inhibits the production of eIF4E, a potent oncogene often upregulated in cancer. The addition of carboplatin and paclitaxel—standard cytotoxic chemotherapies—aims to enhance anticancer activity, with ongoing investigation into the regimen for solid tumors, especially non-small cell lung cancer in combination therapy contexts[5][7].
- Other names
- ISIS 183750 + carboplatin + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))DNAEIF4E (Eukaryotic translation initiation factor 4E)
Beyond the preview
Go deeper on ISIS 183750 + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ISIS 183750 + carboplatin + paclitaxel.